U.S. Markets open in 6 hrs 5 mins

AMAG Pharmaceuticals, Inc. (AMAG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.750.00 (0.00%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.75
Open13.75
Bid0.00 x 3000
Ask0.00 x 34100
Day's Range13.75 - 13.76
52 Week Range4.41 - 13.80
Volume1,534,573
Avg. Volume1,811,067
Market Cap477.47M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?
    Zacks

    AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?

    AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • AMAG (AMAG) to be Acquired by Covis Group for $647 Million
    Zacks

    AMAG (AMAG) to be Acquired by Covis Group for $647 Million

    AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.

  • Amag Pops 45% On Covis Takeover Nod
    SmarterAnalyst

    Amag Pops 45% On Covis Takeover Nod

    Shares of Amag Pharmaceuticals climbed 45.2% on Thursday after the company approved a takeover bid by Covis Pharma. The transaction is expected to be completed in November this year.Covis will pay $13.75 in cash for each outstanding shares of Amag Pharmaceuticals (AMAG), representing a premium of 46% from the stock's closing price of $9.40 on Sept. 30. According to Amag, the deal is valued at “approximately $498 million on a fully diluted basis and approximately $647 million on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash.”Covis CEO Michael Porter said, “AMAG’s category leading treatments are strong strategic complements to our existing therapeutic portfolio. Through this combination, we believe we will be able to unlock value for all of our stakeholders, employees and patients through the effective and efficient management of these products, coupled with our two companies’ longstanding commitment to expanding patient access to therapy and putting patient interests first.” (See AMAG stock analysis on TipRanks)Needham analyst Serge Belanger welcomed the takeover announcement but reiterated a Hold rating on the stock. In a note to investors on Oct. 1, Belanger said, “We view the Covis acquisition offer for AMAG as a fair acquisition bid. We believe AMAG has been widely shopped and thus don't expect any additional competitive bids before an anticipated transaction close in November.”Currently, the Street is sidelined on the stock with a Hold analyst consensus. With shares up nearly 12.2% year-to-date, the average analyst price target of $11.21 implies downside potential of 17.9% from current levels.Related News: AstraZeneca’s Covid-19 Vaccine Put On Fast Track By EU Regulator Caesars To Buy William Hill In $3.7B Deal; Stifel Raises PT Regeneron: Initial Data From REGN-COV2 Trial Shows Promise, but Capacity Remains an Issue More recent articles from Smarter Analyst: * Boeing Wins $298M US Contract For Satellite System * Goldman Sachs To Snap Up GM’s Credit Card Unit For $2.5B - Report * Google To Pay Media Outlets $1B For News Content * Ligand Closes $438M Pfenex Deal; Street Sees 84% Upside